Drug Trial Radar · NCT02756364
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
Last checked: Nov 20, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Jul 28, 2016
Primary completion
Nov 25, 2019
Study completion Nov 25, 2019
Sponsor
- Lead sponsor
- Calithera Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.
Conditions
- Breast Neoplasms
Interventions
FulvestrantDrug
Fulvestrant IM injection.
SapanisertibDrug
Sapanisertib capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to 40 months
Locations
53 sites in 2 countries. Site status is shown where the registry gives one.
Southern Cancer Center, PC
Mobile, Alabama
CBCC Global Research 6501 Truxtun Avenue Bakersfield, CA
Bakersfield, California
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
Fullerton, California
UCSD Moores Cancer Center
La Jolla, California
UCLA Hematology/Oncology David Geffen School of Medicine
Los Angeles, California
North County Oncology
Oceanside, California
Torrance Health Association
Redondo Beach, California
PHC-SLO Oncology and Hematology
San Luis Obispo, California
Cancer Center of Santa Barbara With Sansum Clinic
Santa Barbara, California
University of Colorado Cancer Center-Anschutz Cancer Pavilion (ACP)
Aurora, Colorado
St. Mary'S Hospital Regional Cancer Center
Grand Junction, Colorado
Rocky mountain cancer centers LLP
Lakewood, Colorado
Holy Cross Hospital- Bienes Cancer Center
Fort Lauderdale, Florida
Memorial Healthcare System
Hollywood, Florida
Orlando Health Inc.
Orlando, Florida
Ft. Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana
New England Cancer Specialists
Scarborough, Maine
Health Partners Institute Park Nicollet Frauenshuh Cancer Center
Saint Louis Park, Minnesota
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
New Jersey Hematology & Oncology Associates
Brick, New Jersey
Northern Westchester Hospital Cancer Treatment & Wellness Center
Mount Kisco, New York
Oregon Health and Science University
Portland, Oregon
Texas Oncology, P.A.
Austin, Texas
Texas Oncology - Presbyterian Hospital
Dallas, Texas
Texas Oncology, P.A.
Dallas, Texas
Texas Oncology- South Second Street
McAllen, Texas
Cancer Care Centers of South Texas
San Antonio, Texas
Texas Oncology,PA. Tyler TX, 75702
Tyler, Texas
Virginia Cancer Specialist PC
Leesburg, Virginia
West Virginia University School of Medicine
Morgantown, West Virginia
Complejo Hospitalario Universitario A Coruna
A Coruña, Spain
Centro Oncologico de Galicia
A Coruña, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clinic i Provincial
Barcelona, Spain
Hospital De la Santa Creu i Sant Pau
Barcelona, Spain
Hospital San Pedro de Alcantara
Cáceres, Spain
Hospital Universitari Arnau de Vilanova de Lleida
Lleida, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Clinico San Carlos
Madrid, Spain
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.